Objective:

To evaluate the efficacy, safety, and factors associated with long-term benefits and tolerability of PARP inhibitor therapy specifically in elderly patients with advanced ovarian cancer.

Key Findings:

• Of 56 patients, 35.7% received olaparib and 60.7% received niraparib.
• Median progression-free survival (mPFS) was 24 months for patients in the first-line maintenance group.
• Factors associated with longer PFS included CA125 level, CR attainment, BRCA mutation status, and R0 at initial surgery.
• In the PSR group, mPFS was not reached for those with PSR ≥12 months, while it was 9.6 months for those with PSR 6–12 months.
• Anemia was the most common grade 3–4 adverse event in the olaparib group, while thrombocytopenia was more common in the niraparib group.

Interpretation:

Long-term PARP inhibitor use was generally well-tolerated in elderly ovarian cancer patients, with specific clinical factors identified as predictive of better outcomes.

Limitations:

• The study is retrospective and conducted at a single center, which may limit generalizability.
• The sample size was relatively small.
• The lack of diversity in the sample may affect the applicability of the findings.

Conclusion:

PARP inhibitor maintenance therapy yields favorable clinical outcomes for elderly ovarian cancer patients, with specific factors predicting longer PFS.